oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central...

21

Transcript of oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central...

Page 1: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 2: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 3: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 4: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 5: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 6: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 7: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 8: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 9: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 10: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 11: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 12: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 13: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 14: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 15: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 16: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 17: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 18: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 19: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 20: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer
Page 21: oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · National reference labs Central sample collection Marker identification (IGH, t(11;14)) Sequencing and ASO Primer

Slide 2 / 28web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S6-0… · slide 1 / 28 slide 2 / 28 page 1. undefined s6-04 patient-reported outcome (pro) results, nrg oncology/nsabp

Slide 2 / 28web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S6-0… · slide 1 / 28 slide 2 / 28 page 1. undefined s6-04 patient-reported outcome (pro) results, nrg oncology/nsabp

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · -2016 DEC. 6-10 SAN ANTONIO BREAST CANCER SYMPOSIUM Financial disclosure: Consultancy

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · -2016 DEC. 6-10 SAN ANTONIO BREAST CANCER SYMPOSIUM Financial disclosure: Consultancy

Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide

Slide 2 / 20 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-07.… · NEGATIVE ADVANCED BREAST CANCER ENROLLED IN KEYNOTE-028 Speaker: Hope S Rugo Slide

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien... · SABCS 2016. Disclosure of Potential Conflicts of Interest Employment: Immediate Family Member Sandoz

SABCS 2016 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien... · SABCS 2016. Disclosure of Potential Conflicts of Interest Employment: Immediate Family Member Sandoz

oncoletterweb.oncoletter.ch/.../EHA2016/Dumontet.pdf · INTRODUCTION Patients (pts) with multiple myeloma (MM) have an increased risk of infections due to toxicities of therapy, immuno-

oncoletterweb.oncoletter.ch/.../EHA2016/Dumontet.pdf · INTRODUCTION Patients (pts) with multiple myeloma (MM) have an increased risk of infections due to toxicities of therapy, immuno-

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS2015/Larocca.pdf · MYELOMA WORKSHOP Rome. Auditorium Parco della Musica September 23-26, 2015 Geriatric assessment

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS2015/Larocca.pdf · MYELOMA WORKSHOP Rome. Auditorium Parco della Musica September 23-26, 2015 Geriatric assessment

Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival

Slide 2 / 17web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S5-0… · slide 9 / 17 slide 10 / 17 page 5. undefined s5-05 trastuzumab emtansine improves overall survival

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... ·  · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/MWS... ·  · 2015-09-24Common Themes Does patient need treatment If yes, are they fit or frail (2 drugs) Should

Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was

Pretreatment with Prasugrel in Non ST-Segment Elevation ...web.oncoletter.ch/files/cto_layout/Kongressdateien/ECCO ESMO 201… · sponsored by Daiichi Sankyo and Eli Lilly, and was

SABCS 2013 - oncoletterweb.oncoletter.ch/.../Kongressdateien/SABCS2013/S3-06.pdf · 2013. 12. 13. · Dr. Schnitt: Nothing to disclose. 2013 SAN ANTONIO BREAST CANCER SYMPOSIUM .

SABCS 2013 - oncoletterweb.oncoletter.ch/.../Kongressdateien/SABCS2013/S3-06.pdf · 2013. 12. 13. · Dr. Schnitt: Nothing to disclose. 2013 SAN ANTONIO BREAST CANCER SYMPOSIUM .

DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… ·  · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)

DSC 5266 - Willkommen bei oncoletter - Oncoletter, …web.oncoletter.ch/files/cto_layout/Kongressdateien/ASC… ·  · 2014-01-18Metastatic Gastric or Gastroesophageal Junction (GEJ)

Folie001 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/STGALLEN/2... · Characterization of primary tumors Beckman-Coulter Brahms Diapat/Mosaiques DiaSorin Epigenomics

Folie001 - oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/STGALLEN/2... · Characterization of primary tumors Beckman-Coulter Brahms Diapat/Mosaiques DiaSorin Epigenomics

Linfomas de Células B iniciales e indolentes · 2013. 7. 11. · MCL Classical MCL t(11;14) Cyclin D1 Long Latency Periods in the Progression of MCL Christian B et al JCO 2010, ASH

Linfomas de Células B iniciales e indolentes · 2013. 7. 11. · MCL Classical MCL t(11;14) Cyclin D1 Long Latency Periods in the Progression of MCL Christian B et al JCO 2010, ASH

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C05... · Rapido trial, results awaited Locally advanced Rectal Cancer International randomized multicentre

web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASCO-GI 2017/C05... · Rapido trial, results awaited Locally advanced Rectal Cancer International randomized multicentre

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien... · 2016. 12. 10. · First study with CellSearch@, N=118 pts (REMAGUS02) No significant association between CTC detection

Translocation (11;14)(q13;q32) and preferential ...with MCL is t(11;14)(q13;q32), but other variants such as t(11;22) have also been described [23]. Deletion 6q15 and monosomy 13 are

Translocation (11;14)(q13;q32) and preferential ...with MCL is t(11;14)(q13;q32), but other variants such as t(11;22) have also been described [23]. Deletion 6q15 and monosomy 13 are

Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ

Slide 2 / 23 - web.oncoletter.chweb.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2015/S4-0… · slide 1 / 23 slide 2 / 23 page 1. undefined s4-04 lobular carcinoma in situ

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · Double-blind Concordance Study of Breast Cancer Recommendations Between Manipal Multidisc* Tumor

SABCS 2016web.oncoletter.ch/files/cto_layout/Kongressdateien/SABCS2016/SLID… · Double-blind Concordance Study of Breast Cancer Recommendations Between Manipal Multidisc* Tumor

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/... · Cycle 2 Cvcle3-6 Cycle7-24 Follow-Up Daratumumab infusions (First infusion includes pre-dose the before) Lenalidomide

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH... · 2015. 12. 8. · Randomized, double-blind, placebo-controlled study in adult ß-thalasserupatients (including

oncoletterweb.oncoletter.ch/files/cto_layout/Kongressdateien/ASH... · 2015. 12. 8. · Randomized, double-blind, placebo-controlled study in adult ß-thalasserupatients (including